Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.480
-0.080 (-5.13%)
At close: Feb 27, 2026, 4:00 PM EST
1.490
+0.010 (0.68%)
After-hours: Feb 27, 2026, 6:53 PM EST

Fate Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1711131883699805,587
Market Cap Growth
19.89%-39.69%-49.04%-62.39%-82.45%-29.57%
Enterprise Value
45-23-101245865,018
Last Close Price
1.480.981.653.7410.0958.51
PS Ratio
25.6917.0613.795.8010.18100.05
PB Ratio
0.820.550.591.002.038.23
P/TBV Ratio
0.820.550.591.002.038.23
EV/Sales Ratio
6.76--1.956.0989.85
Debt / Equity Ratio
0.380.380.270.280.230.17
Net Debt / Equity Ratio
-0.61-0.61-0.61-0.57-0.67-0.74
Net Debt / EBITDA Ratio
0.930.931.101.231.112.37
Net Debt / FCF Ratio
1.121.121.571.531.152.35
Asset Turnover
0.020.020.030.110.120.07
Quick Ratio
5.675.677.398.134.177.70
Current Ratio
5.795.797.588.484.407.79
Return on Equity (ROE)
-51.84%-51.84%-54.21%-37.76%-48.46%-39.91%
Return on Assets (ROA)
-24.30%-24.30%-25.81%-19.65%-23.69%-17.57%
Return on Capital Employed (ROCE)
-52.20%-52.20%-48.60%-40.80%-52.10%-25.80%
Earnings Yield
-79.85%-120.27%-99.11%-43.64%-28.73%-3.80%
FCF Yield
-65.63%-98.85%-65.77%-37.53%-28.94%-3.82%
Buyback Yield / Dilution
-4.49%-4.49%-15.52%-1.64%-2.19%-15.00%
Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q